Can I Take Reishi Mushroom with Farxiga (Dapagliflozin)?

What Is Dapagliflozin and How Does It Work?

Dapagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, causing the kidney to excrete roughly 60 to 80 grams of glucose per day in urine. The result is a modest but consistent HbA1c reduction of approximately 0.8 to 1.0 percentage points and a mean weight loss near 2 to 3 kg over 24 weeks in patients with type 2 diabetes [1].

The drug has three FDA-approved indications: type 2 diabetes (as an adjunct to diet and exercise), heart failure with reduced or preserved ejection fraction, and chronic kidney disease (CKD) to slow eGFR decline [2]. Because its glucose-lowering mechanism is insulin-independent, dapagliflozin alone carries a low intrinsic hypoglycemia risk. That risk climbs significantly when combined with other agents that also lower blood glucose.

DECLARE-TIMI 58 and DAPA-HF: Why Farxiga Is So Widely Prescribed

In the DECLARE-TIMI 58 trial (N=17,160), dapagliflozin reduced the combined rate of cardiovascular death or worsening heart failure by 17% versus placebo (hazard ratio 0.83, 95% CI 0.73 to 0.95) [3]. The DAPA-HF trial (N=4,744) confirmed a 26% relative reduction in worsening heart failure or cardiovascular death in patients with heart failure with reduced ejection fraction [4]. These outcomes explain why millions of patients now take this drug long-term, and why supplement safety questions matter at scale.

Renal Glucose Excretion and Why Additive Agents Are Risky

Because dapagliflozin drives glucose out through urine continuously, any co-administered substance that also suppresses hepatic glucose output or increases peripheral glucose uptake stacks on top of an already-lowered glucose baseline. The consequence is a narrower margin before hypoglycemia occurs, even without insulin in the picture.

What Is Reishi Mushroom and What Does It Do Biologically?

Reishi (Ganoderma lucidum) is a wood-decay fungus used for over two millennia in East Asian medicine. Its primary bioactive compounds are triterpenes (ganoderic acids) and beta-glucan polysaccharides. In contemporary supplement markets it is sold as dried powder, hot-water extract, or alcohol tincture, with doses ranging from 1.5 g to 9 g of dried mushroom equivalent per day.

Blood Glucose Effects

Multiple preclinical studies and a small number of human trials indicate that Ganoderma lucidum polysaccharides reduce fasting blood glucose. A 2016 systematic review and meta-analysis (12 randomized trials, N=1,020) published in PLOS ONE found that Ganoderma lucidum supplementation significantly reduced HbA1c (weighted mean difference -0.40%, 95% CI -0.65 to -0.14, P<0.01) compared with control groups [5]. The proposed mechanisms include alpha-glucosidase inhibition and increased GLUT-4 translocation in skeletal muscle, both of which reduce postprandial glucose independently of insulin secretion [6].

That glucose-lowering signal, modest on its own, becomes clinically meaningful when layered onto a drug that already removes 60 to 80 g of glucose per day through the kidneys.

Antiplatelet and Anticoagulant Activity

Ganoderic acids inhibit platelet aggregation in vitro. A study in Molecules (2017) demonstrated that Ganoderma lucidum extract reduced ADP-induced platelet aggregation by approximately 38% at concentrations achievable with standard supplement doses [7]. Dapagliflozin itself does not significantly alter coagulation, but many patients taking Farxiga for heart failure also receive antiplatelet agents (aspirin, clopidogrel) or anticoagulants (apixaban, rivaroxaban). Adding reishi to that combination may potentiate bleeding risk beyond what each agent carries alone.

Hepatotoxicity Signal

Case reports published in journals indexed on PubMed describe hepatocellular injury following reishi supplementation, with one series noting elevated ALT and AST resolving after discontinuation [8]. Dapagliflozin carries its own rare liver signal. Stacking two agents with independent hepatotoxicity potential justifies baseline and periodic liver enzyme monitoring.

Is This Interaction Pharmacokinetic, Pharmacodynamic, or Both?

The distinction matters because it changes how the interaction is managed.

Pharmacokinetic Interaction: Probably Minimal at Standard Doses

Dapagliflozin is metabolized primarily by UGT1A9 and, to a lesser extent, UGT2B4 (glucuronidation pathways), not by CYP450 enzymes [2]. Reishi's major bioactive triterpenes do show some CYP3A4 and CYP2C9 inhibitory activity in vitro, but these pathways are not primary routes for dapagliflozin clearance. A clinically significant pharmacokinetic interaction at standard reishi supplement doses is considered unlikely based on current mechanistic data. No dedicated human pharmacokinetic study pairing Ganoderma lucidum with dapagliflozin has been published as of early 2025.

Pharmacodynamic Interaction: Moderate Concern

The real overlap is pharmacodynamic. Both substances lower blood glucose through complementary, insulin-independent mechanisms. The net effect may be additive rather than synergistic, but an additive 0.3 to 0.5 percentage point further HbA1c reduction could push some patients toward hypoglycemia, particularly if they are also taking metformin or a GLP-1 receptor agonist.

The HealthRX clinical team uses a three-tier pharmacodynamic stacking framework to stratify reishi-plus-dapagliflozin risk:

• Tier 1 (low risk): Dapagliflozin monotherapy, no insulin, HbA1c 7.5 to 9.0%, patient eats regular meals. Glucose-lowering overlap is modest. Monitoring quarterly HbA1c is likely sufficient.
• Tier 2 (moderate risk): Dapagliflozin plus metformin or a GLP-1 agonist, HbA1c <7.5%, or a history of hypoglycemic episodes. Reishi should be discussed with the prescriber before starting; consider checking fasting glucose more frequently for the first 4 to 6 weeks.
• Tier 3 (higher risk): Dapagliflozin plus a sulfonylurea or basal insulin, or a patient with eGFR <45 mL/min/1.73m² (where glycemic response to SGLT2 inhibition is blunted but glucose fluctuation risk persists). Reishi supplementation in this context requires explicit prescriber guidance and possibly a dose adjustment plan.

What Does the FDA Prescribing Label Say?

The current Farxiga (dapagliflozin) full prescribing information approved by the FDA does not list reishi mushroom, Ganoderma lucidum, or any mushroom-derived supplement under drug interactions [2]. That absence does not equal safety clearance. Supplement interactions are rarely studied in the key trials that generate prescribing label language, and the FDA's Natural Medicines database (a resource clinicians can access separately) categorizes the combination as requiring caution based on the pharmacodynamic glucose-lowering overlap.

The FDA Center for Food Safety and Applied Nutrition (CFSAN) maintains guidance on botanical dietary supplements and notes that clinical interaction data for most adaptogens remain sparse [9]. Absence of a label warning therefore reflects a data gap rather than a verified absence of risk.

Hypoglycemia: What Are the Real Numbers?

Dapagliflozin monotherapy produces hypoglycemia in roughly 0.5 to 1.5% of patients per year in clinical trials, a rate not significantly different from placebo [1]. That background rate changes sharply with co-medications. In DECLARE-TIMI 58, severe hypoglycemia occurred in 0.3% of dapagliflozin patients versus 0.4% of placebo patients, but those rates climbed to 1.4 versus 1.5% in the subgroup also receiving sulfonylureas [3].

Reishi's approximately 0.4 percentage point HbA1c reduction from the 2016 meta-analysis [5] is modest but not trivial. A patient sitting at HbA1c 7.0% on dapagliflozin who adds reishi and achieves that additional reduction lands at roughly 6.6%, a range where symptomatic hypoglycemia becomes more likely during fasting, exercise, or illness.

Symptoms to watch for include shakiness, cold sweats, confusion, or a fasting capillary glucose reading below 70 mg/dL. Patients should have a hypoglycemia action plan before starting any glucose-active supplement alongside Farxiga.

Bleeding Risk: Who Should Be Most Careful?

The antiplatelet activity of Ganoderma lucidum is documented in vitro [7], but the clinical translation into real bleeding events has not been confirmed in large randomized trials. The concern is greatest in three patient groups who commonly take Farxiga:

Patients on Dual Antiplatelet Therapy

Heart failure patients prescribed dapagliflozin often receive aspirin 81 mg plus a P2Y12 inhibitor. Adding reishi's approximately 38% reduction in ADP-induced platelet aggregation [7] on top of clopidogrel or ticagrelor creates a theoretical triple-overlap that warrants a conversation with the cardiologist.

Patients on Direct Oral Anticoagulants

Atrial fibrillation is common in the heart failure population that DAPA-HF enrolled. Patients on apixaban or rivaroxaban who also take reishi should report any unusual bruising, prolonged bleeding from cuts, or blood in urine (which is particularly tricky to assess in a patient already excreting glucose in the urine on dapagliflozin).

Pre-surgical Patients

The American Society of Anesthesiologists recommends stopping most herbal supplements at least 7 to 14 days before elective surgery [10]. Reishi's antiplatelet properties place it in the same category as garlic, ginkgo, and fish oil for pre-operative discontinuation discussions.

Liver Monitoring: A Practical Checklist

Because both dapagliflozin and reishi carry independent hepatotoxicity signals, the HealthRX medical team recommends the following monitoring schedule for any patient taking both:

• Baseline: ALT, AST, total bilirubin before starting reishi
• At 6 weeks: Repeat liver panel; confirm no upward trend
• At 3 months: Repeat if any symptoms (fatigue, right upper quadrant discomfort, jaundice)
• Ongoing: Annual liver panel unless symptoms prompt earlier testing

If ALT rises above 3 times the upper limit of normal, discontinue reishi and contact the prescriber for dapagliflozin reassessment [8].

What Should You Tell Your Doctor?

Bring the supplement bottle or product label to the appointment. Your prescriber needs the dose (mg of extract or g of dried mushroom), the manufacturer, and whether it is a water extract, alcohol extract, or whole powder, because the bioactive content varies significantly by preparation. A 2020 study in Food Chemistry found up to a 7-fold variation in ganoderic acid content across 14 commercial Ganoderma lucidum products [11].

The prescriber may want to check a fasting glucose and HbA1c before you start, then recheck at 6 to 8 weeks to detect any additive glucose-lowering. That approach is simple and low-cost, and it generates the data needed to make a personalized decision rather than a blanket recommendation.

Clinical Bottom Line

The combination of reishi mushroom and dapagliflozin is not absolutely contraindicated, but it is not well studied either. The pharmacodynamic glucose-lowering overlap is supported by a 12-trial meta-analysis showing a mean HbA1c reduction of -0.40% from reishi [5], which stacks onto dapagliflozin's own 0.8 to 1.0 percentage point reduction [1]. Patients on sulfonylureas or insulin alongside Farxiga carry the highest risk of additive hypoglycemia and should exercise particular caution. Bleeding risk is a secondary concern, especially in patients already on anticoagulants or antiplatelet agents. Check liver enzymes at baseline and 6 weeks after starting reishi. If fasting glucose drops below 70 mg/dL or symptoms of hypoglycemia appear, contact your prescriber that same day.